GTGiovanni Tesoriere

Giovanni Tesoriere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giovanni Tesoriere has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Sonia Emanuele

    Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Biochemistry Building, University of Palermo, 90127 Palermo, Italy

    4 shared publications
  • Daniela Carlisi

    Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Institute of Biochemistry, University of Palermo, 90127 Palermo, Italy

    3 shared publications
  • Renza Vento

    Dipartimento di Scienze Biochimiche, Università degli Studi di Palermo, Via del Vespro 129, 90127 Palermo, Italy

    3 shared publications
  • A. D’aNneo

    Dipartimento di Scienze Biochimiche, Università di Palermo, Policlinico, Italy

    2 shared publications
  • Antonella D'ANneo

    Laboratory of Biochemistry, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via del Vespro 129, 90127 Palermo, Italy

    2 shared publications
  • B. Vassallo

    Dipartimento di Scienze Biochimiche, Università di Palermo, Policlinico, Italy

    2 shared publications

Latest Publications

  • Retraction
    Open Access

    [Retracted] Hsp72 controls bortezomib‑induced HepG2 cell death via interaction with pro‑apoptotic factors

    by Giuseppe Calvaruso, Michela Giuliano, Patrizia Portanova, Ornella Pellerito, Renza Vento, Giovanni Tesoriere

    Subsequently to the publication of the above article, a concerned reader drew the Editor's attention to the fact that specific protein bands featured within the western blots in Figs. 1A, 2B and 4 were strikingly similar. Having assessed these data independently in the Editorial Office, some of the concerns raised by the reader were judged to have been well founded; in particular, the striking similarity of the protein bands shown for the IP AIG + and IP Apaf‑1 + experiments in Fig. 2B, and of a pair of β‑actin bands within the blot for Fig. 1A, such that these striking similarities in the appearance of the abovementioned protein bands, accompanied by the surrounding gel backgrounds, could not easily be attributed to coincidence. Therefore, in view of the probable anomalies that have been identified in this paper, the Editor of Oncology Reports has decided that it should be retracted from the Journal on account of a lack of confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 18: 447‑450, 2007; DOI: 10.3892/or.18.2.447]

  • Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation

    by Daniela Carlisi, Antonella D'ANneo, Liliana Angileri, Marianna Lauricella, Sonia Emanuele, Andrea Santulli, Renza Vento, Giovanni Tesoriere

    This article shows that HepG2, Hep3B, and SK‐Hep1 cells, three lines of human hepatocellular carcinoma (HCC) cells, are resistant to apoptosis induced by tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL). Parthenolide, a sesquiterpene lactone found in European feverfew, has been shown to exert both anti‐inflammatory and anti‐cancer activities. This article demonstrates that co‐treatment with parthenolide and TRAIL‐induced apoptosis with synergistic interactions in the three lines of HCC cells. In order to explain these effects we ascertained that parthenolide increased either at protein or mRNA level the total content of death receptors TRAIL‐R1 and ‐R2 as well as their surface expression. These effects were found in the three cell lines in the case of TRAIL‐R2, while for TRAIL‐R1 they were observed in HepG2 and SK‐Hep1 cells, but not in Hep3B cells. We suggest that the effects of parthenolide on death receptors depend on the decrease in the level of phosphorylated and active forms of STAT proteins, an event which could be a consequence of the inhibitory effect exerted by parthenolide on the activation of JAK proteins. In agreement with this hypothesis treatment with STAT3 siRNA increased in HCC cells the effect of parthenolide on the expression of death receptors. Sensitization by parthenolide to TRAIL stimulated in the three cell lines the extrinsic mechanism of apoptosis with the activation of both caspases 8 and 3, whereas mitochondria were not involved in the process. Our results suggest that co‐treatment with parthenolide and TRAIL could represent a new important therapeutic strategy for hepatic tumors. J. Cell. Physiol. 226: 1632–1641, 2011.


  • SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib

    by S. Emanuele, M. Lauricella, D. Carlisi, B. Vassallo, A. D’aNneo, P. Di Fazio, R. Vento, G. Tesoriere

    Histone deacetylase (HDAC) inhibitors represent a promising group of anticancer agents. This paper shows that the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) stimulated at 5–10 μM apoptosis in human hepatoma HepG2 and Huh6 cells, but was ineffective in primary human hepatocytes (PHH). In HepG2 cells SAHA induced the extrinsic apoptotic pathway, increasing the expression of both FasL and FasL receptor and causing the activation of caspase-8. Moreover, SAHA enhanced the level of Bim proteins, stimulated alternative splicing of the Bcl-X transcript with the expression of the proapoptotic Bcl-Xs isoform, induced degradation of Bid into the apoptotic factor t-Bid and dephosphorylation and inactivation of the anti-apoptotic factor Akt. Consequently, SAHA caused loss of mitochondrial transmembrane potential, release of cytochrome c from mitochondria, activation of caspase-3 and degradation of PARP. Interestingly, a combination of suboptimal doses of SAHA (1 μM) and bortezomib (5–10 nM), a potent inhibitor of 26S proteasome, synergistically induced apoptosis in both HepG2 and Huh6 cells, but was ineffective in PHH. Combined treatment increased with synergistic effects the expression levels of c-Jun, phospho-c-Jun and FasL and the production of Bcl-Xs. These effects were accompanied by activation of Bid, caspase-8 and 3. In conclusion, SAHA stimulated apoptosis in hepatoma cells and exerted a synergistic apoptotic effect when combined with bortezomib. In contrast, these treatments were quite ineffective in inducing apoptosis in PHH. Thus, our results suggest the potential application of the SAHA/bortezomib combination in clinical trials for liver cancer.


  • Bortezomib induces in HepG2 cells IκBα degradation mediated by caspase-8

    by Giuseppe Calvaruso, Michela Giuliano, Patrizia Portanova, Anna De Blasio, Renza Vento, Giovanni Tesoriere

    The present paper demonstrates that the proteasome inhibitor bortezomib, which behaves as an apoptotic agent in hepatoma HepG2 cells, caused in these cells a decrease in IκBα level and a consequent increase in NF-κB activity. The effect already appeared at 4 h of treatment and preceded the onset of apoptosis which was observed at 24 h. Our results demonstrate that bortezomib-induced IκBα degradation occurred in conjunction with the activation of caspase-8; moreover, the decrease in IκBα level was prevented in a dose-dependent manner by the addition of z-IETD, a specific inhibitor of caspase-8. Bortezomib caused the same effects in non-tumor Chang liver cells, which were not susceptible to the apoptotic effect of the drug. Our results also show that other proteases, such as caspase-3 and calpains, exerted only a limited effect on IκBα degradation. These findings suggest that caspase-8 can be involved in the control of IκBα level. In addition, the activation of caspase-8 can exert, at least in the first phase of treatment with bortezomib, a protective effect in both HepG2 and Chang liver cells, favouring the activation of the survival factor NF-κB


  • JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways

    by M. Lauricella, S. Emanuele, A. D’aNneo, G. Calvaruso, B. Vassallo, D. Carlisi, P. Portanova, R. Vento, G. Tesoriere

    The proteasome inhibitor bortezomib is an efficacious apoptotic agent in many tumor cells. This paper shows that bortezomib induced apoptosis in human hepatoma HepG2 cells associated with many modifications in the expression of survival or death factors. Although bortezomib increased the level of the protective factors HSP70 and HSP27, the effects of the drug that favour cell death were predominant. These events include accumulation of c-Jun, phospho-c-Jun and p53; increase in FasL level with activation of caspase-8; changes related to members of Bcl-2 family with increase in the level of pro-apoptotic members and decrease in that of anti-apoptotic ones; dissipation of mitochondrial potential with cytochrome c release and activation of caspase-3. In contrast, Chang liver cells exhibited a very low susceptibility to bortezomib-induced apoptosis, which was accompanied by modest modifications in the expression of apoptotic factors. In HepG2 cells bortezomib markedly increased AP-1 activity and the expression of its transcriptional targets such as c-Jun, FasL, BimEL, which are involved in apoptosis. Moreover, AP-1 induced its own production by increasing c-Jun content in the composition of the same AP-1 complex. In addition, bortezomib caused activation of JNK1, which in turn increased the level of phospho-c-Jun as well as stimulated the activation of caspase-3 and t-Bid, two fundamental apoptotic factors. Interestingly, siRNA silencing of c-Jun or JNK1 reduced HepG2 cell susceptibility to apoptosis and prevented the increase in AP-1 activity. Both JNK-1 and AP-1 thus exerted a crucial role in bortezomib-induced apoptosis. Differently, in Chang liver cells the different composition of AP-1 complex as well as the failure of JNK activation seemed to be responsible for the low susceptibility to apoptosis. Given the high susceptibility of hepatoma cells to bortezomib, our results suggest the potential application of this compound in clinical trials for liver cancers.